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Objective: To investigate the combination of mild mechanical stimuli and a disease modifying osteoar-
thritis drug (DMOAD) in inﬂammatory activated chondrocytes and to study the combination of drug and
mechanical tension on the cellular level as a model for an integrated biophysical approach for osteoar-
thritis (OA) treatments.
Methods: Interleukin-1beta (IL-1b) stimulated C28/I2 cells underwent mild mechanically treatment
while cultured in the presence of the DMOAD diacerein. The pharmacological input of diacerein was
evaluated by cell viability and cell proliferation measurements. Inﬂammation and treatment induced
changes in key regulatory proteins and components of the extracellular matrix (ECM) were characterized
by quantitative real-time PCR (qPCR). The effects on metalloproteinase-1 (MMP-1) activity and glycos-
aminoglycan (GAG) concentration in cell supernatants of treated cells were investigated.
Results: C28/I2 cells demonstrated signiﬁcant changes in expression of inﬂammatory and cartilage
destructive proteins in response to IL-1b stimulation. The chondroprotective action of diacerein in me-
chanically stimulated cells was mediated by a decrease in interleukin-8 (IL-8), ﬁbronectin-1 (FN-1),
collagen type I (Col 1) and MMP-1 expression levels, respectively. Augmented expression of interleukin-6
receptor (IL-6R) and the ﬁbroblast growth factor receptors (FGFRs) by diacerein was not abolished by
mechanical treatment. The observed effects were accompanied by a reduced cell proliferation rate,
attenuated cell viability and extenuated MMP-1 activity.
Conclusion: Diacerein diversely regulates the expression of main regulatory proteins as well as compo-
nents important to regenerate and set up ECM. Mechanical stimulation does not negatively inﬂuence the
chondroprotective effect induced by diacerein treatment in immortalized human C28/I2 chondrocytes.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.3Introduction
Osteoarthritis (OA) is a multifactorial, complex disease affecting
about 15% of the world's population. Worldwide the prevalence of
OA increases steadily and generates an ever rising economic
burden1,2. This joint disease, targets the structural and functional
integrity of articular cartilage. The destruction of cartilage results in
a gradual development of stiffness, limited motion and chronic: B. Steinecker-Frohnwieser,
37; Fax: 43-3685-22323-142.
er-Frohnwieser).
ing 214, A-8962 Gr€obming,
ternational. Published by Elsevier Lpain, the major symptoms of OA . The origin of pain and disability
arises from the pathological imbalance of the dynamic state be-
tween destructive forces and repair mechanisms within the joints4.
Medical treatment of OA mainly involves the application of non-
steroidal drugs (NSAIDs), corticosteroids, or pain relievers like
paracetamol5,6, with deleterious side effects on the gastrointestinal
tract, kidney and liver7; corticosteroid application leads to a pro-
gressive cartilage damage in weight bearing joints and has
numerous other side effects (e.g., Cushing syndrome)8.
Alternatively, current therapies for OA including disease modi-
fying osteoarthritis drugs (DMOADs) try to preserve normal joint
function, reduce disease's intensity and symptoms, and restrain the
progression rate of OA9. The DMOAD diacerein, an anthraquinone,
reduces the severity of OA and may be able to modify the course oftd. All rights reserved.
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regulation of the interleukin-1beta (IL-1b) induced inﬂammatory
pathways, mainly involved in cartilage destruction, thus, sup-
pressing the cartilage-matrix breakdown11e13. At the gene expres-
sion level, diacerein decreases the production of pro-matrix
metalloproteinases (MMPs) involved in cartilage degradation and
augments tissue inhibitor of metalloproteinases-1 (TIMP-1) pro-
duction14,15. Furthermore, studies revealed that diacerein antago-
nizes the IL-1b triggeredmitogen-activated protein kinase (MAPKs)
signaling cascades of articular chondrocytes16. Along with an
observed regulation of transcription factors nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) and activator
protein-1 (AP-1), diacerein seems to stimulate cartilage repair by
up-regulating the expression of transforming growth factor-beta1
(TGF-b1) and b2 even in the absence of IL-1b17.
The summary of several clinical studies performed over the last
20 years implicate that oral intake of diacerein improves symptoms
of patients with hip and knee OA and allows the reduction of NSAID
consumption18e20.
An alternative therapeutic approach, the dynamic loading of
joints in OA patients, demonstrates the effectiveness of non-drug
treatment modalities21,22 such as an increase in cartilage thick-
ness as a consequence of physiological mechanical loading23. In
joints, cartilage function depends on composition and structural
integrity of the cartilage matrix. Mechanical signals like stretch and
ﬂow-induced dynamic compression are utilized by chondrocytes to
maintain the balance between degradation and synthesis of matrix
macromolecules24. Therefore chondrocytes transmit mechanical
signals into a physiological response via different signaling path-
ways including matrix receptors, calcium and/or ion-channels25,26.
Under excessive loading or injury, however, degradation exceeds
synthesis, causing joint degeneration and, eventually, OA27. It has
been shown that physiological mechanical stimulation is able to
inhibit IL-1b induced matrix degradation28,29, whereas increased
peak stress and strain rates provoke cartilage damage30 and
worsens the risk of injury24.
Regeneration of the ECM based on moderate mechanical stim-
ulation combined with the DMOAD diacerein might be beneﬁcial to
slow the progression of the disease. Therefore our study was
designed to investigate the inﬂuence of diacerein combined with
mechanical stimulation on regulatory parameters of the chon-
drocyte cell line C28/I2.
Material & methods
Cell culture
Cells from an immortalized human chondrocyte cell line (C28/
I2, kindly provided by Prof. M.B. Goldring, Harvard Institute of
Medicine, Boston, MA) were cultured in Dulbeco's modiﬁed eagle's
medium (DMEM high glucose; GIBCO, Invitrogen, Darmstadt, Ger-
many) supplemented with 10% fetal bovine serum (FBS; GIBCO,
Invitrogen), 1% L-glutamine (GIBCO, Invitrogen), 100 units/ml
penicillin (GIBCO, Invitrogen), 100 mg/ml streptomycin (GIBCO,
Invitrogen) and 0.25 mg amphotericin B (PAA Laboratories, Pasch-
ing, Austria). Cells were kept at 37C in a humidiﬁed atmosphere of
5% CO2 and passaged by trypsinisation upon reaching conﬂuence.
IL-1b (10 ng/ml, SigmaeAldrich, US) was added 24 h after seeding.
It has been shown that C28/I2 cells are suitable for the study of
mechano-signaling of chondrocytes31,32.
Cell proliferation and viability assay
MTS assay (Brand, Voerde-Friedrichsfeld, Germany) was used to
measure themetabolic activity of cells: 5103 C28/I2 cells per wellwere seeded into 96 well plates and the CellTiter 96 AQueous Assay
(Promega, Mannheim, Germany) was performed following the
manufacturers' instructions after 1, 6, and 24 h. Untreated cells
were used as negative controls.
The xCELLigence DP device from Roche Diagnostics (Mannheim,
Germany) was used to monitor the proliferation of cells seeded on
electronic microtiter plates (E-Plate; Roche Diagnostic) in real-
time33. Cells were treated with different concentrations of diacer-
ein as speciﬁed and measured for 24 h. Cell density measurements
were performed in triplicates with signal detection every 20 min.
The cell index (CI) is a measure for the cell density of cells and was
normalized to the time point of addition of diacerein/IL-1b.
Acquisition and analysis was performed with the RTCA software
(Version 1.2, Roche Diagnostics).
Determination of MMPs
Cells were plated in six well plates and treated with ±IL-1b for 3
days after which the supernatants were collected. Duplicate su-
pernatants were pooled and diluted 2.5 fold in dilution buffer.
Detection of MMP-1, -3, and -13 in the supernatants was done ac-
cording to the Fluorokine MAP Human MMP Kit manufacturer's
instruction (R&D Systems Europe, Abington, UK). The micro parti-
cles were detected using the Luminex200System (Luminex Cor-
poration, Austin, US). The reader was set to read a minimum of 100
beads with identical unique detection signal and the results were
expressed as median ﬂuorescent intensity (MFI).
The levels of both, the endogenous active MMP-1 and the MMP-
1 in these samples that can be activated by p-Amino-
phenylmercuric Acetate (APMA) were measured quantitatively by
the Human Active MMP-1 Fluorescent Assay (R&D, Minneapolis,
US). The active MMP-1 of cell culture supernatants from mechan-
ical stimulated and diacerein/IL-1b treated cells (50 ml) were
measured according to the manufacturer's manual. The measured
ﬂuorescent signal (320 nm/405 nm) is proportional to the amount
of enzyme activity in the sample.
IL-6 and IL-8 determination
Ready-to-use Sandwich ELISAs (human IL-6 and human IL-8
Platinum ELISA, eBioscience, San Diego USA) were used to quan-
tify IL-6 and IL-8. Supernatants were used undiluted or diluted as
required from 1:5 to 1:100 and proceeded according to the man-
ufacturer's instruction. All measurements were performed in du-
plicates at 450 nm with micro plate reader SpectraMax Plus 384
(Molecular Devices, Sunnyvale, US) or Anthos 2010 (Anthos Labtec
Instruments GesmbH., Wals, Austria).
Reverse transcription polymerase chain reaction (RT-PCR)
Total ribonucleic acid (RNA) was isolated from treated and un-
treated cells with the RNeasy Mini Kit and DNase-I treatment ac-
cording to the manufacturer's manual (Qiagen, Hilden, Germany).
Quantiﬁcation and quality control of the isolated RNA was accom-
plished by determining the optical density at A260 as well as the
A260/A280 ratio by a NanoPhotometer (Implen, Munich, Germany)
and by denaturing agarose gel electrophoresis.
One microgram RNAwas reverse transcribed for 30 min at 37C
(iScriptcDNA Synthesis Kit, BioRad, Hercules, USA). The sequences
of the PCR primers and the sizes of the amplicons are given in
Table I. Col-II quantitative RT-PCR (qPCR) was performed with the
QuantiTect primer assay (Qiagen). All other primer sequences were
derived from the Primerbank database (http://pga.mgh.harvard.
edu/primerbank). Reactions were performed in duplicates. Ampli-
ﬁcation was achieved with the RealMasterMix SYBR ROX (5 Prime,
Table I
Sequences of primer-pairs used for quantitative RT-PCR are given; the amplicon sizes to be expected are listed in the very right column
Gene (accession nr.) Forward primer Reverse primer Amplicon size (bp)
MMP-1 50CTGTTCAGGGACAGAATGTGCT30 50TCGATATGCTTCACAGTTCTAGGG30 85
MMP-13 50TCCTCTTCTTGAGCTGGACTCATT3 50CGCTCTGCAAACTGGAGGTC30 97
IL-6 50AAATTCGGTACATCCTCGACGG30 50GGAAGGTTCAGGTTGTTTTCTGC30 112
IL-8 50ACTGAGAGTGATTGAGAGTGGAC30 50AACCCTCTGCACCCAGTTTTC30 112
Col I (NM_000088) 50GTTCAGCTTTGTGGACCTCCG30 50CTTGGTCTCGTCACAGATCAC30 235
Col-XII (NM_001852) 50CCTCCCTGGTGAGATTGGAAT30 50TTGGTTGGACACAGGAAATCC30 147
FN1 50CCCCATTCCAGGACACTTCTG30 50GCCCACGGTAACAACCTCTT30 203
ITGb1 (NM_002211) 50CAAGCAGGGCCAAATTGTGG30 50CCTTTGCTACGGTTGGTTACATT30 185
NF-kB 50GCCTGACTTTGAGGGACTGTA30 50CTAGATGCAAGGCTGTTCGTC30 137
TGF-b (NM_000660) 50CAAGCAGAGTACACACAGCAT30 50TGCTCCACTTTTAACTTGAGCC30 129
JNK1 (NM_002750) 50AGAAGCTAAGCCGACCATTTC30 50TCTAGGGATTTCTGTGGTGTGA30 133
IL-6R (NM_181359) 50CCCCTCAGCAATGTTGTTTGT30 50CTCCGGGACTGCTAACTGG30 171
EGFR (NM_005228) 50AAGGAAATCCTCGATGAAGCCT30 50TGTCTTTGTGTTCCCGGACATA30 154
FGFR (NM_000142) 50TCCTTGCACAACGTCACCTTT30 50GCAGAGTGATGAGAAAACCCAA30 83
VEGFA (NM_001171627) 50CGCAGCTACTGCCATCCAAT30 50GTGAGGTTTGATCCGCATAATCT30 192
GAPDH (NM_002046) 50TGATGACATCAAGAAGGTGGTGAAG30 50TCCTTGGAGGCCATGTGGGCCAT30 102
Aldolase (NM_000034) 50ATGAGTCCACTGGGAGCATTG30 50ACCGCCCTTGGATTTGATAAC30 209
ETIF (NM_003753) 50CTACCAGCCGTTCAGCAAAG30 50CACCACCAAACTGAGAGGAGT30 110
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Hamburg, Germany). Each qPCR run consisted of a standard 3-step
PCR temperature protocol (annealing temperature of 60C) fol-
lowed by a melting curve protocol to conﬁrm a single gene-speciﬁc
peak and to detect primer dimerization. Relative quantiﬁcation of
expression levels were obtained by the DDCt method based on the
geometric mean of the internal controls glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), aldolase, and eukaryotic
translation initiation factor 3 (ETIF), respectively. Assessment of the
ratio values is based on the calculation of changes in the relative
expression for all genes of interest (control vs treated groups) by
the DDCt method. For the IL-1b stimulation [Fig.1] DCt values of the
unstimulated cells functioned as control. For all other experiments
the control group was from cells stimulated with IL-1b. The ratio
values for treated and untreated groups were calculated according
to the formula: r ¼ 2DDCt from which the percent change was
derived.
Mechanical stimulation of C28/I2 cells
The Flexercell FX-5000 Tension System (FX5K; Flexcell Inter-
national Corp, Hillsborough, USA) was used to apply mechanical
cyclic tensile stretch on chondrocytes. This system uses ﬂexible
silicon membranes (BioFlex plates) in six well-plates. The defor-
mation of the ﬂexible bottom causes the attached cells to deform.
Programming of the magnitude, duration, and frequency of the
negative pressure in the Flexercell apparatus creates desired strain
proﬁles34.
Chondrocytes were seeded (5  104 cells/well) onto the
pronectin-coated BioFlex plates, using six wells per treatment
group. After the cells reached 70e80% conﬂuence, chondrocytes
were subjected to a continuous cyclic mechanical strain proﬁle with
tension cycles lasting 2 s each (0.5 Hz). The elongation was applied
as a sinusoidal curve with a maximum displacement of 10%. The
stimulationwas repeatedly applied for 8 h and followed by 4 h rest.
While stretching, the cultures were kept in an incubator for cell
culture (37C, 5% CO2). Control cultures were grown under the
same conditions but without the strain protocol.
Assay for total collagen and glycosaminoglycan (GAG) synthesis
After mechanical stimulation for 24 h, total collagen and
GAG synthesis were measured in cell culture supernatants in trip-
licates by the Sircol dye assay (Biocolor, Newtownabbey, UK)according to the manufacturer's instructions. Absorbance was
measured at 555 nm. The calibration curve was set up on the basis
of a collagen standard provided by the manufacturer.
GAG amount was measured using the Blyscan 1,9-
dimethylmethylene blue (DMMB) assay kit (Biocolor) according
to the manufacturer's instructions. Absorbance was measured at
656 nm. The calibration curve was set up on the basis of a collagen
standard provided by the manufacturer.
Statistical analysis
RT-qPCR as well as ELISA experiments were performed in du-
plicates. Data were analyzed by the ShapiroeWilk test for
normality and presented as mean (±standard deviation) or as
median and the 25th and 75th percentile. Comparison of two
groups was accomplished by use of a two-sample t-test (parametric
data) or with ManneWhitney rank sum test (non-parametric data).
For multiple comparisons the one way analysis of variance
(ANOVA) followed by the HolmeSidak test was used. Probability
values smaller than 0.05 were considered signiﬁcant. Data analysis
was performed with the SigmaPlot software (Systat Software Inc.,
Erkrath, Germany).
Results
IL-1b changed the expression of IL-6, IL-8 and MMP-13 in C28/I2
cells
To characterize their inﬂammatory state, C28/I2 cells were
treated with IL-1b over a period of 3 days and the inﬂuence on
biomarkers involved in inﬂammation was measured by qPCR.
The expression of MMP-13 was increased 8.7 (4.9, 9.8) fold
(median (25th, 75th percentile)), IL-6 3.2 (2.4, 4.7) fold and the
expression of IL-8 by a factor of 15.6 (14.0, 22.9), whereas MMP-1
was reduced to 52% (21%, 72%) and MMP-3 to 39% (30%, 56%) of
their original values [Fig. 1(A)]. IL-1b induced the augmentation of
IL-6 (46.2 ± 2.9 ng/ml vs control 5.1 ± 0.5 ng/ml) and IL-8
(150.5 ± 22.8 ng/ml vs control 4.2 ± 0.5 ng/ml) [Fig. 1(B)]. The in-
crease of IL-8 by IL-1b stimulation was 5-fold more pronounced
than for IL-6. The high basal expression of MMP-1 (22.9 ± 6.4 ng/
ml) at the protein level explains the small relative change ofMMP-1
messengerRNA (mRNA) (0.5 fold) when cells were exposed to IL-1b
[Fig. 1(C)]. Protein concentrations for MMP-3 and MMP-13 differed
only slightly from control values.
Fig.1. Changes of gene expression in C28/I2 cells under inﬂammatory conditions. (A) The expression of the matrix metalloproteinases MMP-1, -3, -13 and the interleukins IL-6 and
IL-8 were analyzed at RNA and protein levels from C28/I2 chondrocytes treated with IL-1b over a period of 3 days. All three bar charts represent the median values with the 75th and
25th percentile. Gene expression analysis was performed by qPCR. The bar chart under (A) represents the level of gene expression under IL-1b (10 ng/ml) when compared to
controls. (B) The concentrations of IL-6 and IL-8 were determined by ELISA and (C) for MMP-1, -3 and -13 by the Fluorokine MAP Human MMP Kit and Luminex technique.
Signiﬁcance levels are given by P values of the ManneWhitney Rank Sum Test (*: P < 0.05; **: P < 0.01; ***P < 0.001); n is the number of experiments; all measurements were
performed in duplicates. The 100% value for no change is marked by the dashed line.
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cells
The inﬂuence of different concentrations of diacerein on cell
viability and proliferation over a period of 24 h was tested with the
MTS tetrazolium assay. Cells grown in the presence of 100 mM
diacerein for 24 h demonstrated a signiﬁcant reduction in cell
viability by 28.6 ± 1.07% [Fig. 2(A)].Analysis of cell proliferation monitored in real time revealed no
changes for 1 mM or 10 mM but for 100 mM diacerein compared to
control conditions as demonstrated by the CI [Fig. 2(B)]. The in-
ﬂuence of IL-1b in combination with different concentrations of
diacerein was also tested [Fig. 2(C)]. The addition of IL-1b changed
the CI only at concentrations of 30 mM and 100 mM diacerein
[Fig. 2(C)]. Lower concentrations of diacerein were without effects.
Accordingly, 100 mM diacerein caused an increase of the calculated
Fig. 2. Viability and cell proliferation of C28/I2 cells treated with different concentrations of diacerein. (A) Viability of cells treated with different concentrations of diacerein was
assessed with the MTS assay. Shown are the mean values and standard deviations of four experiments whereas per experiment each value was determined in quadruplicates. (B)The
inﬂuence of different concentrations of diacerein on cell growth was measured in real time with an impedance based cell proliferation assay (xCELLigence) over a period of 24 h.
Mean values ± standard deviations of the normalized CI of four experiments with 3e5 fold determinations are given. (C) Time course of the CI with IL-1b treatment in the presence
of different concentrations of diacerein. (D) From the dynamic monitoring of cell proliferation the doubling time was calculated (mean ± standard deviation, n ¼ 7e9). Level of
signiﬁcance (*: P < 0.05) was determined by the Student's t test.
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and from 32.7 ± 2.6 h to 517.3 ± 146 h in the presence of IL-1b
[Fig. 2(D)].Fig. 3. Inﬂuence of diacerein and mechanical stimulation on gene expression under
inﬂammatory conditions. C28/I2 cells were grown on pronectin coated six-well BioFlex
plates in the presence of IL-1b. The bar chart represents the qPCR data as for the level
of expression in mechanical stimulated and mechanical stimulated plus diacerein
(100 mM) treated chondrocytes compared to control. The single bars represent theChanges in gene expression by diacerein and mechanical stimulated
C28/I2 cells
To elicit an inﬂammatory state at the cellular level chon-
drocytes were grown in the presence of IL-1b. Mechanical stim-
ulation slightly increased the expression of IL-6 by 20% and
signiﬁcantly decreased the expression of IL-8 to 84% (77%, 92%) of
control [Fig. 3]. Diacerein at a concentration of 100 mM had no
additional effect on IL-6 but further reduced the pro-inﬂammatory
modulator IL-8 to 58% (55%, 62%) of its control value. Even though
in IL-1b treated cells, the expression of NF-kB was not changed
under mechanical stimulation, the addition of diacerein produced
a 1.5 fold (to 154% (134%, 238%)) increase. While expression of the
transforming growth factor beta (TGF-b) was not inﬂuenced, in-
duction in expression of the mitogen-activated protein kinase 8
(JNK1) was demonstrated when the cells were simultaneously
stimulated mechanically and with diacerein (to 198% (175%, 213%),
Fig. 3).median and the 75th and 25th percentile. Percent values are based on the ratio values
which were calculated by normalization to the results gained from cells treated only
with IL-1b. Statistic evaluation is based on differences in DCt values. Signiﬁcance levels
evaluated by the ManneWhitney Rank Sum Test are *: P < 0.05; **: P < 0.01; þþ:
P < 0.01. Cells grown with IL-1b and without mechanical stimulation or diacerein
served as control.Inﬂuence on MMP-1 activity and GAG production of chondrocytes
To evaluate the inﬂuence of diacerein and the mechanical
stimulation separately and as a combined treatment modality, the
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supernatants of control chondrocytes stimulated only with IL-1b
were compared to supernatants of cells which were grown in IL-1b
containing medium and stimulated mechanically or stimulated in
the presence of diacerein. The application of diacerein in the
absence of mechanical stimulation induced GAG production
(29.5 ± 3.9 mg/ml) compared to control values (1.9 ± 0.7 mg/ml).
Mechanical stimulation had no inﬂuence on diacerein induced
production of GAG. Cell supernatants of cells treated with diacerein
and mechanically displayed 26.1 ± 3.8 mg/ml GAG (control:
0.76 ± 0.65 mg/ml, Fig. 4(A)). The MMP-1 activity was unchanged by
the IL-1b treatment in C28/I2 cells; IL-1b combined with diacerein
signiﬁcantly reduced MMP-1 activity to 57% [Fig. 4(B)]. Under
mechanical stimulation even though IL-1b had no effect, the
presence of diacerein decreased the MMP-1 activity by 54%. This
decrease was less marked in cells additionally stimulated me-
chanically (1.2 ± 0.05 ng/ml) when compared to cells without
mechanical treatment (0.94 ± 0.05 ng/ml).
Regulation of the ECM by mechanical stimulation and diacerein
Cells were mechanically stimulated with and without diacerein
in the presence of IL-1b for 24 h. The mechanical stimulation
signiﬁcantly reduced both collagen type XII (Col 12) and ﬁbronectinFig. 4. GAGs content and matrix metalloproteinase-1 (MMP-1) activity changes by the
treatment with diacerein. (A) Cell supernatants of C28/I2 cells were analyzed for the
GAG content and in addition, (B) the activity of MMP-1 was measured. Data are given
as mean ± standard deviation, ***P < 0.001, þþ: P < 0.01.(FN1) expression levels by 25e30%. Diacerein further augmented
these effects to 42% for Col 12 and to 55% of control for FN1 [Fig. 5].
A decrease in collagen type I (Col 1) andMMP-1 by 50%, integrin-b1
(ITG-b1) by 19 ± 9% as well as, an increase in collagen type II (Col 2)
by 54 ± 40% were only detectable when mechanical stimulation
was combined with the diacerein treatment. The mechanical
stimulation alone induced signiﬁcant changes only for FN1 and Col
12 [Fig. 5].
Changes in expression of interleukin-6 receptor (IL-6R), ﬁbroblast
growth factor receptor (FGFR) and vascular endothelial/growth
factor-A (VEGF-A) by diacerein and mechanical stimulation
The expression levels of important receptors involved in in-
ﬂammatory signal transduction were determined under diacerein
and/or mechanical stimulation. Both the expression of the IL-
6R and the FGFR were up regulated more than 2 fold by diacerein.
This up regulation was independent of the mechanical stimulation
[Fig. 6]. In contrast, the expression of the EGFR appeared to be down
regulated by the mechanical stimulation by 30% [Fig. 6]. Diacerein
without mechanical stimulation induced the up regulation of the
vascular endothelial growth factor-A (VEGF-A) to 270 ± 20%, a
change to 230 ± 18%was detected under diacerein plus mechanical
stimulation [Fig. 6].
Discussion
The mechanical stimulation applied to IL-1b treated chon-
drocytes consisted of a dynamic tensile stretch protocol. Whether
this simpliﬁed mechanical model represents the actual physiolog-
ical stress situation in articular cartilage is unknown. Chondrocytes
in the superﬁcial layers of the cartilage are exposed to tensile strain
and a frequency of 0.5 Hz is typical for jogging or fast walking and it
is conceived that stretching of the chondrocytes is a mechanical
input leading to initiation of downstream signaling events and
adaption of cells and cartilage to mechanical stress35. Dynamic
compression36 as well as hydrostatic pressure37 has been shown to
increase expression of aggrecan and Col 2. We did not observe an
increase in Col 2 due to our mechanical loading protocol but this
could also reﬂect an effect of the IL-1b treatment.
C28/I2 human chondrocytes under IL-1b changed into an in-
ﬂammatory state, demonstrated by an increase in expression of the
pro-inﬂammatory factors IL-6, IL-8 and MMP-13. IL-6 levels have
been demonstrated to be increased signiﬁcantly in the synovial
ﬂuid of patients with rheumatoid arthritis (RA) or OA38, IL-8 is
known for its role in inﬂammation and plays a critical part in
developing pain39. MMP-1 and MMP-13 function as interstitial
collagenases and are well characterized to degrade type II collagen
in cartilage, a crucial step in the progression of OA. Regarding these
pro-inﬂammatory factors diacerein preserved its chon-
droprotective properties even under mechanical stimulation
demonstrated by down regulating the expression of MMP-1, IL-6
and IL-8.
The applied concentration of diacerein (104 M) reduced the cell
viability to 30% while in accordance with the slowdown of cell
growth both facts point to diacerein modulating cellular physi-
ology. Rhein, the metabolite of diacerein, has been demonstrated to
induce anti-catabolic and anti-proliferative effects on chondrocytes
stimulated by IL-1b at similar concentrations (105 M and 104 M).
Both effects were explained by alterations in cell cycle regulation
and not by induction of apoptosis40. In our observation, the increase
in the doubling time of diacerein treated cells was more pro-
nounced in cells under IL-1b treatment, suggesting that diacerein is
more effective under inﬂammatory conditions. A higher sensitivity
of cells in an inﬂammatory state against the toxic effects of
Fig. 5. Changes in expression of relevant genes controlling ECM as tested by qPCR. RNAs of the three different groups: IL-1b alone, IL-1b/mechanical stimulation and IL-1b/me-
chanical stimulation/diacerein (100 mM) were used to perform qPCR reactions. Controls for calculating ratio values were C28/I2 cells not mechanically or diacerein stimulated but
grown in the presence of IL-1b. Levels of expression compared to control are given in percent. Changes of the expression proﬁle of Col 1, Col 2, Col 12, ﬁbronectin (FN-1), met-
alloproteinases MMP-1, and -13 as well as ITG-b1 are given. Statistical evaluation by the Student's t test is based on changes in DCt values (*: P < 0.05; **: P < 0.01; ***: P < 0.001).
Signiﬁcant changes induced through diacerein application under mechanical stimulation are marked by þ: P < 0.05; þþ: P < 0.01; þþþ: P < 0.001.
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under mechanical stimulation may reﬂect an irritating effect which
is completely blunted by diacerein and could be part of the anti-
inﬂammatory effects of diacerein. The mechanical as well as the
diacerein induced decrease in IL-8 expression coincides further
with ﬁndings that physiological mechanical signals antagonize ef-
fects of catabolic mediators involving pro-inﬂammatory cytokines
and transcription factors24. In articular chondrocytes diacerein has
been found to antagonize the IL-1b triggered extracellular signal-
regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK) and
p38 kinase pathways, for their part activating NF-kB and AP-115,16.
Interestingly, magnitude-dependent signals of mechanical strain
utilize the NF-kB transcription factors as common elements to
abrogate or aggravate pro-inﬂammatory responses41. Although its
transcriptional up regulation is not equivalent to its activation in a
signaling pathway, the observed effects indicate an increased
turnover and interference of diacereinwith this pathway. However,
the down regulation by diacerein of the inﬂammatory cytokines IL-
6 and IL-8, which are NF-kB target genes, does not suggest that
activation of the NF-kB pathway is an important element of the
diacerein effect.
The TGF-b expressionwas unchanged even though diacerein has
been reported to stimulate cartilage repair by up-regulating the
expression of TGF-b1 and b2 even in the absence of IL-1b17.
The progressive degeneration of ECM components is one of the
hallmarks of OA. Independent of the mechanical stimulation,diacerein increased the concentration of GAGs in the cell culture
supernatant of chondrocytes which might contribute to the re-
covery of damaged cartilage.
The ability of diacerein in antagonizing the inﬂammatory ac-
tivity of IL-1b is further reﬂected by the strong substances-induced
reduction of the MMP-1 activity even in the presence of IL-1b and
under mechanical stimulation. Diacerein decreased the MMP-1
activity whereas the mechanical stimulation slightly attenuated
this reduction. The expression ofMMP-1 and ofMMP-13, twomajor
enzymes responsible for Col 1 breakdown, has already been found
to be down regulated by diacerein14,15. In addition to a reduced
collagen proteolysis, in diacerein treated cells also the mRNA level
of Col 2 was increased, accompanied by a reduction in Col 1
expression12,42. Under diacerein treatment combined with me-
chanical stimulation the same converse effect was observed, indi-
cating that mild mechanical stimulation does not negatively
inﬂuence the anabolic action of diacerein to ECM.
In OA, the ﬁbronectin content is markedly increased in the
altered matrix due to an increased synthesis by chondrocytes43.
Proteolytic fragments of ﬁbronectin could stimulate the catabolism
of articular cartilage thus, promoting the degeneration of cartilage
in OA44. Mechanical stimulation and the diacerein treatment could
exert their antirheumatic effect by a reduction in the expression of
ﬁbronectin.
Mild mechanical stimulation up-regulated Col 1 and MMP-1.
These potentially pro-inﬂammatory effects of the mechanical
Fig. 6. Increased expression of IL-6R, FGFR and VEGF-A under non-mechanical and
mechanical stimulation of C28/I2 cells by diacerein. Cells were stimulated with IL-1b
alone, IL-1b/diacerein (100 mM), IL-1b/mechanical stimulation and IL-1b/mechanical
stimulation/diacerein (100 mM) for 24 h; the isolated RNAwas used for qPCR reactions.
Changes of the expression of IL-6R, epidermal growth factor receptor (EGFR), FGFR and
vascular endothelial growth factor A (VEGF-A) are shown. Data are given as
mean ± standard deviation. Controls for calculating ratio values were C28/I2 cells not
mechanically or diacerein stimulated but grown in the presence of IL-1b. Statistical
evaluation by one way ANOVA and the HolmeSidak test with *: P < 0.05;
***: P < 0.001; and þ: P < 0.05; þþþ: P < 0.001.
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diacerein treatment. A possibly important effect because diacerein
also increased the expression of the IL-6 receptor, thus, sensitizing
cells for the effect of IL-6. On the other hand an increase in expres-
sion of the potentially pro inﬂammatory factors MMP-13 and VEGF-
A induced by diacerein was hardly modulated by the mechanical
stimulation. A synergistic negative regulatory effect was observed
on Col 12, ﬁbronectin and to a lesser extent on the ﬁbronectin re-
ceptor ITGb1 so that onewould expect amutual ampliﬁcation of the
effects of mechanical stimulation and diacerein treatment. The up
regulation of the FGFR3 expression by diacerein alone and under
mechanical stimulation might contribute to the increase of GAGs
due to the fact that FGFR3 and its selective ligand FGF18 were
identiﬁed to stimulate proteoglycan synthesis45. The down regula-
tion of EGFR by the combined diacerein andmechanical stimulation
may contribute to its anti-inﬂammatory effect since under inﬂam-
matory conditions EGFR is overexpressed in RA synovial tissues46.
The aim of our study was to test whether the combination of
two methods involved in OA treatment differs from applications
with only a single method and how diacerein treatment interferes
with effects of the mechanical stimulation. In order to ﬁrst achieve
insights into affected molecular mechanisms we performed our
study at the cellular level.
Taken together diacerein treatment, even in the presence of
mechanical stimulation could have a chondroprotective effect.
These data for the ﬁrst time indicate that mechanical tension and
diacerein treatment applied in combination might be beneﬁcial in
OA treatment but this has to be shown in clinical trials. Addition-
ally, due regard must be given to the fact that our test system is an
immortalized cell line and clinical studies for conformation are of
profound necessity.
Authors' contributions
Bibiane Steinecker-Frohnwieser made substantial contributions
to the conception and design of the project, the acquisition, analysisand interpretation of the data, drafted the article and approved the
version to be submitted. Lukas Weigl participated in study's design
and interpretation of the data, revised the article for important
intellectual content and contributed to the ﬁnal approval of the
article. Werner Kullich contributed to the conception and design of
the project, revised the article critically and approved the version to
be submitted. Birgit Lohberger was involved in acquisition of the
data, revising the article and the ﬁnal approval of the version to be
submitted. Werner Kullich head of the Boltzmann Institute Saal-
felden (lbirehab@aon.at) takes responsibility for the integrity of the
work, from inception to ﬁnished article.
Role of the funding source
The study was supported by the basic research budget of the Lud-
wig Boltzmann Gesellschaft and by grants of the Austrian Pension
Insurance Company. Both institutions did not take part in study
design, collection, analysis and interpretation of the data as well as
the writing of the manuscript and the decision to submit the
manuscript for publication.
Competing interest statement
The authors declare that they have no competing interests.
Acknowledgments
The authors thank Heike Kaltenegger and Nicole Stuendl
(Medical University of Graz, Austria) for excellent technical assis-
tance and Prof. MB Goldring from the Harvard Institute of Medicine
(Boston, US) who kindly provided the C28/I2 chondrocytes.
References
1. Chen A, Gupte C, Akhtar K, Smith P, Cobb J. The global eco-
nomic cost of osteoarthritis: how the UK compares. Arthritis
2012;2012:698709.
2. Suri P, Morgenroth DC, Hunter DJ. Epidemiology of osteoar-
thritis and associated comorbidities. PM R 2012;4:S10e9.
3. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update
with relevance for clinical practice. Lancet 2011;377:2115e26.
4. Goldring MB. Chondrogenesis, chondrocyte differentiation,
and articular cartilage metabolism in health and osteoarthritis.
Ther Adv Musculoskelet Dis 2012;4:269e85.
5. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G,
McGowan J, et al. American College of Rheumatology 2012
recommendations for the use of nonpharmacologic and
pharmacologic therapies in osteoarthritis of the hand, hip, and
knee. Arthritis Care Res (Hoboken) 2012;64:465e74.
6. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD,
Arden NK, et al. OARSI recommendations for the management
of hip and knee osteoarthritis: part III: changes in evidence
following systematic cumulative update of research published
through January 2009. Osteoarthr Cartil 2010;18:476e99.
7. Berenbaum F. New horizons and perspectives in the treatment
of osteoarthritis. Arthritis Res Ther 2008;10(Suppl 2):S1.
8. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G.
Intraarticular corticosteroid for treatment of osteoarthritis of
the knee. Cochrane Database Syst Rev 2006:CD005328.
9. Davies PS, Graham SM, MacFarlane RJ, Leonidou A,
Mantalaris A, Tsiridis E. Disease-modifying osteoarthritis
drugs: in vitro and in vivo data on the development of
DMOADs under investigation. Expert Opin Investig Drugs
2013;22:423e41.
10. Leeb BF. Clinical efﬁciency and safety of diacerein in osteoar-
thritis e a review. Eur Muscoskel Rev 2010:23e8.
B. Steinecker-Frohnwieser et al. / Osteoarthritis and Cartilage 22 (2014) 1044e1052105211. Toegel S, Pabst M, Wu SQ, Grass J, Goldring MB, Chiari C, et al.
Phenotype-related differential alpha-2,6- or alpha-2,3-
sialylation of glycoprotein N-glycans in human chondrocytes.
Osteoarthr Cartil 2010;18:240e8.
12. Pujol JP, Felisaz N, Boumediene K, Ghayor C, Herrouin JF,
Bogdanowicz P, et al. Effects of diacerein on biosynthesis ac-
tivities of chondrocytes in culture. Biorheology 2000;37:
177e84.
13. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM,
Pelletier JP. In vitro effects of diacerhein and rhein on inter-
leukin 1 and tumor necrosis factor-alpha systems in human
osteoarthritic synovium and chondrocytes. J Rheumatol
1998;25:753e62.
14. Alvarez-Soria MA, Herrero-Beaumont G, Sanchez-Pernaute O,
Bellido M, Largo R. Diacerein has a weak effect on the catabolic
pathway of human osteoarthritis synovial ﬁbroblast e com-
parison to its effects on osteoarthritic chondrocytes. Rheu-
matology (Oxford) 2008;47:627e33.
15. Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S,
Pujol JP, et al. Rhein, a diacerhein-derived metabolite, modu-
lates the expression of matrix degrading enzymes and the cell
proliferation of articular chondrocytes by inhibiting ERK and
JNK-AP-1 dependent pathways. Clin Exp Rheumatol 2007;25:
546e55.
16. Domagala F, Martin G, Bogdanowicz P, Ficheux H, Pujol JP.
Inhibition of interleukin-1beta-induced activation of MEK/ERK
pathway and DNA binding of NF-kappaB and AP-1: potential
mechanism for Diacerein effects in osteoarthritis. Biorheology
2006;43:577e87.
17. Felisaz N, Boumediene K, Ghayor C, Herrouin JF,
Bogdanowicz P, Galerra P, et al. Stimulating effect of diacerein
on TGF-beta1 and beta2 expression in articular chondrocytes
cultured with and without interleukin-1. Osteoarthr Cartil
1999;7:255e64.
18. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled
clinical studies with diacerein in the treatment of osteoar-
thritis. Arch Intern Med 2006;166:1899e906.
19. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis.
Cochrane Database Syst Rev 2006:CD005117.
20. Brahmachari B, Chatterjee S, Ghosh A. Efﬁcacy and safety of
diacerein in early knee osteoarthritis: a randomized placebo-
controlled trial. Clin Rheumatol 2009;28:1193e8.
21. Miller GD, Rejeski WJ, Williamson JD, Morgan T, Sevick MA,
Loeser RF, et al. The Arthritis, Diet and Activity Promotion Trial
(ADAPT): design, rationale, and baseline results. Control Clin
Trials 2003;24:462e80.
22. van Baar ME, Dekker J, Oostendorp RA, Bijl D, Voorn TB,
Lemmens JA, et al. The effectiveness of exercise therapy in
patients with osteoarthritis of the hip or knee: a randomized
clinical trial. J Rheumatol 1998;25:2432e9.
23. Fransen M, McConnell S, Bell M. Exercise for osteoarthritis of
the hip or knee. Cochrane Database Syst Rev 2003:CD004286.
24. Bader DL, Salter DM, Chowdhury TT. Biomechanical inﬂuence
of cartilage homeostasis in health and disease. Arthritis
2011;2011:979032.
25. Huselstein C, Netter P, de Isla N, Wang Y, Gillet P, Decot V, et al.
Mechanobiology, chondrocyte and cartilage. Biomed Mater
Eng 2008;18:213e20.
26. Chen C, Tambe DT, Deng L, Yang L. Biomechanical properties
and mechanobiology of the articular chondrocyte. Am J Physiol
Cell Physiol 2013;305:C1202e8.
27. Sun HB. Mechanical loading, cartilage degradation, and
arthritis. Ann N Y Acad Sci 2010;1211:37e50.28. Torzilli PA, Bhargava M, Chen CT. Mechanical loading of
articular cartilage reduces IL-1-induced enzyme expression.
Cartilage 2011;2:364e73.
29. Torzilli PA, Bhargava M, Park S, Chen CT. Mechanical load in-
hibits IL-1 induced matrix degradation in articular cartilage.
Osteoarthr Cartil 2010;18:97e105.
30. Chen CT, Bhargava M, Lin PM, Torzilli PA. Time, stress, and
location dependent chondrocyte death and collagen damage
in cyclically loaded articular cartilage. J Orthop Res 2003;21:
888e98.
31. Hamamura K, Zhang P, Zhao L, Shim JW, Chen A, Dodge TR,
et al. Knee loading reduces MMP13 activity in the mouse
cartilage. BMC Musculoskelet Disord 2013;14:312.
32. Leong DJ, Li YH, Gu XI, Sun L, Zhou Z, Nasser P, et al. Physio-
logical loading of joints prevents cartilage degradation
through CITED2. FASEB J 2011;25:182e91.
33. Xing JZ, Z L, Jackson JA, Gabos S, Sun XJ. Dynamic monitoring of
cytotoxicity on microelectronic sensors. Chem Res Toxicol
2005;18:154e61.
34. Vande Geest JP, D E, Vorp DA. An analysis of the complete
strain ﬁeld within Flexercell membranes. J Biomech 2004;37:
1923e8.
35. Huang J, Ballou LR, Hasty KA. Cyclic equibiaxial tensile strain
induces both anabolic and catabolic responses in articular
chondrocytes. Gene 2007;404:101e9.
36. Shieh AC, Athanasiou KA. Dynamic compression of single cells.
Osteoarthr Cartil 2007;15:328e34.
37. Toyoda T, Seedhom BB, Kirkham J, Bonass WA. Upregulation of
aggrecan and type II collagen mRNA expression in bovine
chondrocytes by the application of hydrostatic pressure. Bio-
rheology 2003;40:79e85.
38. Jikko A, Wakisaka T, Iwamoto M, Hiranuma H, Kato Y, Maeda T,
et al. Effects of interleukin-6 on proliferation and proteoglycan
metabolism in articular chondrocyte cultures. Cell Biol Int
1998;22:615e21.
39. Atta ur R, Harvey K, Siddiqui RA. Interleukin-8: an autocrine
inﬂammatory mediator. Curr Pharm Des 1999;5:241e53.
40. Legendre F, Heuze A, Boukerrouche K, Leclercq S,
Boumediene K, Galera P, et al. Rhein, the metabolite of diac-
erhein, reduces the proliferation of osteoarthritic chon-
drocytes and synoviocytes without inducing apoptosis. Scand J
Rheumatol 2009;38:104e11.
41. Agarwal S, Deschner J, Long P, Verma A, Hofman C, Evans CH,
et al. Role of NF-kappaB transcription factors in antiin-
ﬂammatory and proinﬂammatory actions of mechanical sig-
nals. Arthritis Rheum 2004;50:3541e8.
42. Toegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB,
et al. Comparison between chondroprotective effects of
glucosamine, curcumin, and diacerein in IL-1beta-stimulated
C-28/I2 chondrocytes. Osteoarthr Cartil 2008;16:1205e12.
43. Chevalier X. Fibronectin, cartilage, and osteoarthritis. Semin
Arthritis Rheum 1993;22:307e18.
44. Martin JA, Buckwalter JA. Effects of ﬁbronectin on articular
cartilage chondrocyte proteoglycan synthesis and response to
insulin-like growth factor-I. J Orthop Res 1998;16:752e7.
45. Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G, et al.
Fibroblast growth factor (FGF) 18 signals through FGF receptor
3 to promote chondrogenesis. J Biol Chem 2005;280:
20509e15.
46. Swanson CD, Akama-Garren EH, Stein EA, Petralia JD, Ruiz PJ,
Edalati A, et al. Inhibition of epidermal growth factor receptor
tyrosine kinase ameliorates collagen-induced arthritis.
J Immunol 2012;188:3513e21.
